Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 278, Issue -, Pages 185-189Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2014.11.004
Keywords
Multiple sclerosis; B lymphocytes; MicroRNA; MMP-9; miR-320a
Categories
Funding
- National Institute of Neurological Disorders and Stroke [K23NS052553]
- Robert E. Leet and Clara Guthrie Patterson Trust Award Program in Clinical Research
- NIH [NS059869, NS073994, AT006868]
- Michael J. Fox Foundation for Parkinson's Research
Ask authors/readers for more resources
B cells are necessary to maintain disease activity in relapsing multiple sclerosis (MS) and produce matrix metallopeptidase-9 (MMP-9), which disrupts the blood-brain barrier. MMP-9 protein expression was increased and expression of microRNA-320a (miR-320a), which targets MMP-9 mRNA, was significantly decreased in B lymphocytes of MS patients during a disease relapse compared to remission. Functional significance of these findings was demonstrated by transfecting human B lymphocytes with miR-320a inhibitor, which led to increased MMP-9 expression and secretion. In summary, expression of miR-320a is decreased in B cells of MS patients and may contribute to increased blood-brain barrier permeability and neurological disability. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available